Close Menu

NEW YORK (GenomeWeb) – Illumina said today that it expects that its third quarter 2016 revenues will fall short of its previously anticipated $625 million to $630 million.

The genetic analysis technologies company said in a statement prior to releasing its full Q3 results that it expects total revenues of $607 million, a 10 percent increase over its Q3 2015 revenues of $550 million, but short of its guidance.

The shortfall was driven by a "larger than anticipated year-over-year decline in high-throughput sequencing instruments," the company said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.

Science has retracted a 2007 paper from a former Dutch minister and his colleagues, according to Retraction Watch.

The New York Times reports that a plan to cull minks in Denmark to prevent the spread of a new SARS-CoV-2 strain led to calls for the prime minister's resignation.

In Science this week: winner of the Science & SciLifeLab Prize for Young Scientists, and more.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology.